To date, no studies have proven efficacious in breast cancer patients, but this could be due to the absence of a proper biomarker as tumor expression of PKCβ has not been evaluated in trial participants [(61, 62); clinicaltrials.gov]. This evidence concerns the gene PRKCB and breast carcinoma.